Boehringer Ingelheim develops breakthrough medicines and vaccines for both human and animal health. The company focuses on areas with high unmet medical needs, including oncology, respiratory diseases, metabolic conditions, and infectious diseases across species. With deep expertise in research and development, the company brings scientific innovations from discovery through to global delivery. Founded in 1885 and still family owned, Boehringer Ingelheim operates across more than 130 markets with 54,300 colleagues worldwide. The business invests heavily in long-term research, dedicating over 22% of revenue to R&D. This independence allows the company to prioritise patient and animal outcomes over short term pressures.
54300
Team Members
1885
Founded
Pharma
Sector
Hybrid
Work Environment
A world where people and animals everywhere live longer, healthier lives supported by breakthrough medical science and sustained access to care.
At Boehringer Ingelheim, our mission is to improve the health of people and animals everywhere in the world through innovative medicines and vaccines.